Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.037 ◽

2021 ◽

Vol 154 ◽

pp. 35-45

Author(s):

Banu K. Arun ◽

Hyo S. Han ◽

Bella Kaufman ◽

Hans Wildiers ◽

Michael Friedlander ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Subgroup Analysis ◽

Randomised Clinical Trial ◽

Efficacy And Safety ◽

First Line ◽

Breast Cancer Subgroup

Download Full-text

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study

European Journal of Cancer ◽

10.1016/j.ejca.2013.04.011 ◽

2013 ◽

Vol 49 (12) ◽

pp. 2621-2632 ◽

Cited By ~ 37

Author(s):

Mario Campone ◽

Thomas Bachelot ◽

Michael Gnant ◽

Ines Deleu ◽

Hope S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Subgroup Analysis ◽

Advanced Breast ◽

Efficacy And Safety ◽

Breast Cancer Subgroup ◽

Visceral Metastases

Download Full-text

Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.571 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 571-571 ◽

Cited By ~ 2

Author(s):

John Crown ◽

Richard S. Finn ◽

Johannes Ettl ◽

Katalin Boer ◽

Ravi Patel ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Subgroup Analysis ◽

Advanced Breast ◽

Efficacy And Safety ◽

First Line ◽

Estrogen Receptor Positive

Download Full-text

Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.575 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 575-575

Author(s):

Richard S. Finn ◽

John Crown ◽

Johannes Ettl ◽

Tamas Pinter ◽

Anu Thummala ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Clinical Efficacy ◽

Subgroup Analysis ◽

Safety Profile ◽

Systemic Treatment ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

First Line Treatment

Download Full-text

Faculty of 1000 evaluation for Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718030851.793482493 ◽

2013 ◽

Author(s):

Joanne Jordan ◽

Amanda Nelson

Keyword(s):

Clinical Trial ◽

Sustained Release ◽

Hip Osteoarthritis ◽

Randomised Clinical Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Parallel Group

Download Full-text

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2010.04508.x ◽

2010 ◽

Vol 33 (2) ◽

pp. 213-224 ◽

Cited By ~ 22

Author(s):

Y. Kinoshita ◽

K. Ashida ◽

M. Hongo ◽

Keyword(s):

Clinical Trial ◽

Reflux Disease ◽

Randomised Clinical Trial ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyx001 ◽

2017 ◽

Vol 47 (5) ◽

pp. 385-392 ◽

Cited By ~ 3

Author(s):

Norikazu Masuda ◽

Masato Takahashi ◽

Kazuhiko Nakagami ◽

Yasuhiro Okumura ◽

Takahiro Nakayama ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Japanese Patients ◽

Phase Iii ◽

First Line ◽

Breast Cancer Subgroup

Download Full-text

Retracted: Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.13334 ◽

2015 ◽

Vol 42 (7) ◽

pp. 845-854 ◽

Cited By ~ 20

Author(s):

J. Sun ◽

C. Yang ◽

H. Zhao ◽

P. Zheng ◽

J. Wilkinson ◽

...

Keyword(s):

Clinical Trial ◽

Gastroesophageal Reflux Disease ◽

Gastroesophageal Reflux ◽

Clinical Efficacy ◽

Reflux Disease ◽

Gastrointestinal Symptoms ◽

Randomised Clinical Trial ◽

Efficacy And Safety ◽

Upper Gastrointestinal Symptoms ◽

Upper Gastrointestinal

Download Full-text

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

Breast Cancer Research ◽

10.1186/bcr3600 ◽

2014 ◽

Vol 16 (1) ◽

Cited By ~ 17

Author(s):

Vivien HC Bramwell ◽

Alan B Tuck ◽

Judith-Anne W Chapman ◽

Pieter H Anborgh ◽

Carl O Postenka ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Early Breast Cancer ◽

Randomised Clinical Trial ◽

Correlative Study

Download Full-text

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text